FDA

152498601

Flexion Therapeutics Stumbles on Clinical Hold

In the after-hours on Wednesday, Flexion Therapeutics Inc. (NASDAQ: FLXN) made a hard fall on the news of a clinical hold. Usually clinical holds result in some serious fall out ...
Read Full Story »
research

NPS Pharma Enters Cautionary Phase of the FDA Approval Process

NPS Pharmaceuticals Inc. (NASDAQ: NPSP) is trading lower on what sounded like good news. The problem is that headlines often do not reveal the underlying story. After its shares were ...
Read Full Story »
145922793

Does New Data Make or Break NPS Pharmaceuticals?

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is up huge in regular trading on Wednesday, due to positive preliminary results of a clinical trial. The FDA has posted the briefing materials prior to ...
Read Full Story »
research

Huntington’s Disease Orphan Drug Designation Could Rescue Prana

Prana Biotechnology Ltd. (NASDAQ: PRAN) saw its shares surge on Friday. This movement is on the heels of the U.S. Food and Drug Administration (FDA) granting an orphan drug designation to ...
Read Full Story »
DNA

What This Skin Cancer Drug Approval Really Means to Merck

Merck & Co. Inc. (NYSE: MRK) has received approval from the FDA to bring its new drug to market. The drug is called Keytruda and it is designed to treat ...
Read Full Story »
health care

ELIQUIS Approved for Deep Vein Thrombosis and Pulmonary Embolisms

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) had approved the drug ELIQUIS, as a treatment for Deep Vein Thrombosis and Pulmonary ...
Read Full Story »
186171981

Can Tekmira Make Much Money From Its Ebola Treatment?

Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR) has made a name for itself pioneering new experimental treatments in the wake of the most recent Ebola scare. Ebola is considered one of the deadliest ...
Read Full Story »
biotech

Should Investors Really Be Chasing Potential Ebola Treatments?

The world is dealing with Ebola outbreaks and scares again. We are also in the midst of debates as to whether two Americans who contracted Ebola in Africa should have been ...
Read Full Story »
biotech

5 Huge Biotech Catalysts Right Around the Corner for Top Stocks

A brand new research report from RBC highlights more than 50 biotech event catalysts that are on the horizon. These are trial data, FDA decisions and company presentations coming soon. The ...
Read Full Story »
biotech

4 Key Positive Biotech Stock Catalysts Coming Very Soon

Investors and speculators often flock to the world biotech for emerging drugs of the future. It is no secret at all that the biotech sector is full of all sorts ...
Read Full Story »
biotech

The Path to FDA Approval Could Launch Seven Biotech Stocks Much Higher

Over the years biotech investors who have owned the right stocks have made some very big money on Federal Drug Administration (FDA) approval of leading drug candidates. Typically biotech firms ...
Read Full Story »
76764023

Poll: Where Does MannKind Stock Go in 2015 After Afrezza Approval?

MannKind Corp. (NASDAQ: MNKD) has seen its shares surge on news that it has finally won U.S. Food & Drug Administration backing. This FDA approval for Type 1 and 2 ...
Read Full Story »
biotech

Why Insmed Could Still Double

Insmed Inc. (NASDAQ: INSM) shares were screaming higher on Wednesday. This is just days after we featured it this last weekend as one of three stocks that could double. While ...
Read Full Story »
76764023

The MannKind Lifeline Lights Up

MannKind Corp. (NASDAQ: MNKD) could have been and should have been featured in our Analyst Stocks to Buy Under $10 For Huge Upside this weekend, but MannKind is such a ...
Read Full Story »
153576724

Orexigen Irony: No VIVUS Bounce

VIVUS Inc. (NASDAQ: VVUS) investors have a lot to be disappointed about these days. America's ballooning waistline is reaching a critical level, yet VIVUS did not even manage to close ...
Read Full Story »